<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530842</url>
  </required_header>
  <id_info>
    <org_study_id>205.334</org_study_id>
    <nct_id>NCT00530842</nct_id>
  </id_info>
  <brief_title>Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD</brief_title>
  <official_title>Effect of Inhalation of a Free Combination of Tiotropium Once Daily 18 Mcg and Salmeterol Twice Daily 50 Mcg Versus a Fixed Combination of Fluticasone and Salmeterol Twice Daily (500/50 Mcg) on Static Lung Volumes and Exercise Tolerance in COPD Patients (a Randomised, Double-blind, Double Dummy, 16 (2 x 8) Weeks, Crossover Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate that treatment with a free combination
      of tiotropium and salmeterol provides superior improvement in static lung volumes and
      exercise tolerance compared to a fixed combination of fluticasone and salmeterol in patients
      with COPD.

      The secondary objective includes assessment of safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Post-dose TGV(FRC) (After 8 Weeks)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose TGV(FRC) (Thoracic Gas Volume; co-primary endpoint) after 8 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endurance Time (After 8 Weeks)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Endurance time to the point of symptom limitation after 8 weeks during a constant work rate exercise test at 75% Wcap (co-primary endpoint)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-dose TGV(FRC) (After 4 Weeks)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose TGV(FRC) (Thoracic Gas Volume) after 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endurance Time (After 4 Weeks)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Endurance time to the point of symptom limitation after 4 weeks during a constant work rate exercise test at 75% Wcap (co-primary endpoint)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough TGV(FRC) (Thoracic Gas Volume) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough TGV(FRC) (Thoracic Gas Volume) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough RV (Residual Volume) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough RV (Residual Volume) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose RV (Residual Volume) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose RV (Residual Volume) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough IC (Inspiratory Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough IC (Inspiratory Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose IC (Inspiratory Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose IC (Inspiratory Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough IRV (Inspiratory Reserve Volume) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough IRV (Inspiratory Reserve Volume) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose IRV (Inspiratory Reserve Volume) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose IRV (Inspiratory Reserve Volume) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough TLC (Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough TLC (Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose TLC (Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose TLC (Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes (Percent)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough RV/TLC (Residual Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes (Percent)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough RV/TLC (Residual Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes (Percent)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose RV/TLC (Residual Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes (Percent)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose RV/TLC (Residual Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes (Percent)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes (Percent)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes (Percent)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Volumes (Percent)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slow Vital Capacity (SVC)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough SVC (Slow Vital Capacity) after 8 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slow Vital Capacity (SVC)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough SVC (Slow Vital Capacity) after 4 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slow Vital Capacity (SVC)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose SVC (Slow Vital Capacity) after 8 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slow Vital Capacity (SVC)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose SVC (Slow Vital Capacity) after 4 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough FEV1 (Forced Expiratory Volume in 1 second) after 8 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough FEV1 (Forced Expiratory Volume in 1 second) after 4 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) after 8 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) after 4 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 8 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 4 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 8 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 4 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Over FVC (Percent)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Trough FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Over FVC (Percent)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trough FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Over FVC (Percent)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Over FVC (Percent)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Intensity During Exercise</measure>
    <time_frame>8 weeks</time_frame>
    <description>Isotime Borg dyspnea scale after 8 weeks, Unit on a Scale (min. 0, max 10), 0 = no dyspnea, 10 = worst imaginable dyspnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Intensity During Exercise</measure>
    <time_frame>4 weeks</time_frame>
    <description>Isotime Borg dyspnea scale after 4 weeks, Unit on a Scale (min. 0, max. 10), 0 = no dyspnea, 10 = worst imaginable dyspnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Intensity During Exercise</measure>
    <time_frame>8 weeks</time_frame>
    <description>Isotime Borg leg discomfort scale after 8 weeks, Unit on a Scale (min. 0, max. 10), 0 = no leg dyscomfort, 10 = worst imaginable leg dyscomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Intensity During Exercise</measure>
    <time_frame>4 weeks</time_frame>
    <description>Isotime Borg leg discomfort scale after 4 weeks, Unit on a Scale (min. 0, max. 10), 0 = no leg dyscomfort, 10 = worst imaginable leg dyscomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea and Leg Discomfort</measure>
    <time_frame>8 weeks</time_frame>
    <description>Peak Borg dyspnea scale after 8 weeks, Unit on a Scale (min. 0, max 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea and Leg Discomfort</measure>
    <time_frame>8 weeks</time_frame>
    <description>Peak Borg leg discomfort scale after 8 weeks, Unit on a Scale (min. 0, max 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locus of Symptom Limitation at Peak Exercise During Exercise</measure>
    <time_frame>baseline</time_frame>
    <description>Reason for stopping exercise at baseline (leg discomfort, breathing discomfort, both or none)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locus of Symptom Limitation at Peak Exercise During Exercise</measure>
    <time_frame>4 weeks</time_frame>
    <description>Reason for stopping exercise after 4 weeks (leg discomfort, breathing discomfort, both or none)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locus of Symptom Limitation at Peak Exercise During Exercise</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reason for stopping exercise after 8 weeks (leg discomfort, breathing discomfort, both or none)</description>
  </secondary_outcome>
  <enrollment type="Actual">344</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium plus Salmeterol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/Salmeterol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient has signed an Informed Consent Form in accordance with GCP and local
             legislative requirements prior to participation in the trial, i.e., prior to pre-trial
             washout of any restricted medications.

          2. The patient has a clinical diagnosis of chronic obstructive pulmonary disease (COPD).

          3. The patient has relatively stable, moderate to severe airway obstruction.

          4. The patient has a pre-bronchodilator forced expiratory volume in the first second
             (FEV1) less than or equal to 65% of predicted normal determined at Visit 1 using the
             following predicted equations (R94-1408):

               1. Males Forced expiratory volume in the first second (FEV1) predicted [Litres (L)]
                  = 4.30 x Height [metres] minus 0.029 x Age [years] minus 2.49

               2. Females Forced expiratory volume in the first second (FEV1) predicted [Litres
                  (L)] = 3.95 x Height [metres] minus 0.025 x Age [years] minus 2.60 and a Thoracic
                  Gas Volume (Functional residual volume) ((TGV)(FRC)) bigger than 120% predicted
                  normal at visit 1 (or historical data not older than 6 month)

               3. Males Thoracic Gas Volume (Functional residual volume) ((TGV(FRC)) pred. [Litres
                  (L)] = 2.34 x Height [metres] + 0.009 x Age [years] minus 1.09

               4. Females Thoracic Gas Volume (Functional residual volume) ((TGV(FRC)) pred.
                  [Litres (L)] = 2.24 x Height [metres] + 0.001 x Age [years] minus 1.00

          5. The patient is at least 40 years and less than or equal to 75 years old.

          6. The patient has a cigarette smoking history of at least 10 pack-years. A pack-year is
             defined as the equivalent of smoking one pack of cigarettes per day for a year.

          7. The patient is able to perform all specified procedures and able to maintain all
             necessary records during the study period as required in the protocol.

          8. The patient is able to inhale the trial medication from the HandiHaler device.

          9. The patient is able to inhale the trial medication from the Diskus/Accuhaler device.

        Exclusion Criteria:

          1. a significant disease other than chronic obstructive pulmonary disease (COPD). (review
             contraindications for exercise testing),

          2. a recent history of myocardial infarction within one year.

          3. a recent history of heart failure, pulmonary oedema, or patients with cardiac
             arrhythmia or any contraindication to exercise described in the CTProtocol within the
             last 3.

          4. daytime supplemental oxygen.

          5. a diagnosis of known active tuberculosis.

          6. a history of cancer within the last 5 years.

          7. a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis
             or bronchiectasis.

          8. thoracotomy with pulmonary resection.

          9. an upper respiratory tract infection or an exacerbation of chronic obstructive
             pulmonary disease (COPD)

         10. a known hypersensitivity to anticholinergic drug, ß-adrenergic or corticosteroids,
             lactose or any other component of the inhalation capsule delivery system.

         11. a known symptomatic prostatic hypertrophy or bladder neck obstruction.

         12. a known moderate or severe renal insufficiency.

         13. a known narrow-angle glaucoma.

         14. a known untreated hypokalemia.

         15. a known untreated thyrotoxicosis.

         16. a history of asthma, allergic rhinitis or atopy, or a total blood eosinophil count
             larger than 600/mm3.

         17. treatment with cromolyn sodium or nedocromil sodium

         18. treatment with antihistamines or antileukotrienes.

         19. treatment with tiotropium for 1 month before Visit 1.

         20. treatment with oral corticosteroid medication.

         21. Pregnant or nursing women or women of childbearing potential not using a medically
             approved means of contraception

         22. a history of or active alcohol or drug abuse.

         23. an investigational drug within 1 month or 10 half lives

         24. a limitation of exercise performance as a result of factors other than fatigue or
             exertional dyspnoea.

         25. participation in a rehabilitation program for chronic obstructive pulmonary disease
             (COPD).

         26. treatment with monoamine oxidase inhibitors inhibitors or tricyclic antidepressants.

         27. participation in another study.

         28. more than eight puffs of salbutamol/day during the run-in period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.334.4309 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gänserndorf</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.4308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hallein</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.4306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.4301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.4302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neumarkt am Wallersee</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.4305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.1009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.1003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.1005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.1008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.1004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.1010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.1001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.1007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.1006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beuvry</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beuvry</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.3306B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.3302B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.4908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.4909 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.4904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donaustauf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.4901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.4907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.4902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaiato Pavullo (mo)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.7001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.7002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.7003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.334.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2007</study_first_submitted>
  <study_first_submitted_qc>September 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <results_first_submitted>December 30, 2009</results_first_submitted>
  <results_first_submitted_qc>February 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2010</results_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participant flow data are presented by treatment sequence</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tiotropium + Salmeterol / Fluticasone + Salmeterol</title>
          <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. / Flu+Sal 500+50mcg b.i.d.</description>
        </group>
        <group group_id="P2">
          <title>Fluticasone + Salmeterol / Tiotropium + Salmeterol</title>
          <description>Flu+Sal 500+50mcg b.i.d. / Tio 18mcg o.d. + Sal 50mcg b.i.d.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Individual different reasons</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Individual different reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Individual different reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tiotropium + Salmeterol / Fluticasone + Salmeterol</title>
          <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. / Flu+Sal 500+50mcg b.i.d.</description>
        </group>
        <group group_id="B2">
          <title>Fluticasone + Salmeterol / Tiotropium + Salmeterol</title>
          <description>Flu+Sal 500+50mcg b.i.d. / Tio 18mcg o.d. + Sal 50mcg b.i.d.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="172"/>
            <count group_id="B2" value="172"/>
            <count group_id="B3" value="344"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="7.5"/>
                    <measurement group_id="B2" value="60.6" spread="7.6"/>
                    <measurement group_id="B3" value="61.0" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-dose TGV(FRC) (After 8 Weeks)</title>
        <description>Post-dose TGV(FRC) (Thoracic Gas Volume; co-primary endpoint) after 8 weeks</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values. The full analysis set (FAS) was defined to include all treated patients with any post-dosing efficacy data after at least 4 weeks for both investigational treatments in TGV(FRC) or endurance time.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose TGV(FRC) (After 8 Weeks)</title>
          <description>Post-dose TGV(FRC) (Thoracic Gas Volume; co-primary endpoint) after 8 weeks</description>
          <population>FAS using imputed values. The full analysis set (FAS) was defined to include all treated patients with any post-dosing efficacy data after at least 4 weeks for both investigational treatments in TGV(FRC) or endurance time.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.99" spread="0.07"/>
                    <measurement group_id="O2" value="5.07" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0482</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with fixed terms for sequence, treatment, and period and random term for subject within sequence.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.087</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.174</ci_lower_limit>
            <ci_upper_limit>-0.001</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endurance Time (After 8 Weeks)</title>
        <description>Endurance time to the point of symptom limitation after 8 weeks during a constant work rate exercise test at 75% Wcap (co-primary endpoint)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Endurance Time (After 8 Weeks)</title>
          <description>Endurance time to the point of symptom limitation after 8 weeks during a constant work rate exercise test at 75% Wcap (co-primary endpoint)</description>
          <population>FAS using imputed values</population>
          <units>Seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463" spread="375" lower_limit="316" upper_limit="691"/>
                    <measurement group_id="O2" value="453" spread="413" lower_limit="307" upper_limit="720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3407</p_value>
            <method>Wilcoxon signed−rank test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>27.5</ci_upper_limit>
            <estimate_desc>The confidence interval was determined by Hodges−Lehmann method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose TGV(FRC) (After 4 Weeks)</title>
        <description>Post-dose TGV(FRC) (Thoracic Gas Volume) after 4 weeks</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose TGV(FRC) (After 4 Weeks)</title>
          <description>Post-dose TGV(FRC) (Thoracic Gas Volume) after 4 weeks</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="0.07"/>
                    <measurement group_id="O2" value="5.19" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endurance Time (After 4 Weeks)</title>
        <description>Endurance time to the point of symptom limitation after 4 weeks during a constant work rate exercise test at 75% Wcap (co-primary endpoint)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Endurance Time (After 4 Weeks)</title>
          <description>Endurance time to the point of symptom limitation after 4 weeks during a constant work rate exercise test at 75% Wcap (co-primary endpoint)</description>
          <population>FAS using imputed values</population>
          <units>Seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458" spread="331" lower_limit="343" upper_limit="674"/>
                    <measurement group_id="O2" value="450" spread="375" lower_limit="301" upper_limit="676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Trough TGV(FRC) (Thoracic Gas Volume) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Trough TGV(FRC) (Thoracic Gas Volume) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" spread="0.08"/>
                    <measurement group_id="O2" value="5.25" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Trough TGV(FRC) (Thoracic Gas Volume) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Trough TGV(FRC) (Thoracic Gas Volume) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.32" spread="0.08"/>
                    <measurement group_id="O2" value="5.34" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Trough RV (Residual Volume) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Trough RV (Residual Volume) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" spread="0.08"/>
                    <measurement group_id="O2" value="4.25" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Trough RV (Residual Volume) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Trough RV (Residual Volume) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" spread="0.08"/>
                    <measurement group_id="O2" value="4.35" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Post-dose RV (Residual Volume) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Post-dose RV (Residual Volume) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" spread="0.07"/>
                    <measurement group_id="O2" value="4.07" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Post-dose RV (Residual Volume) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Post-dose RV (Residual Volume) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="0.07"/>
                    <measurement group_id="O2" value="4.14" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Trough IC (Inspiratory Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Trough IC (Inspiratory Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="0.04"/>
                    <measurement group_id="O2" value="2.23" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Trough IC (Inspiratory Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Trough IC (Inspiratory Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.04"/>
                    <measurement group_id="O2" value="2.23" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Post-dose IC (Inspiratory Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Post-dose IC (Inspiratory Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="0.04"/>
                    <measurement group_id="O2" value="2.35" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Post-dose IC (Inspiratory Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Post-dose IC (Inspiratory Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="0.05"/>
                    <measurement group_id="O2" value="2.37" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Trough IRV (Inspiratory Reserve Volume) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Trough IRV (Inspiratory Reserve Volume) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.04"/>
                    <measurement group_id="O2" value="1.41" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Trough IRV (Inspiratory Reserve Volume) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Trough IRV (Inspiratory Reserve Volume) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.04"/>
                    <measurement group_id="O2" value="1.42" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Post-dose IRV (Inspiratory Reserve Volume) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Post-dose IRV (Inspiratory Reserve Volume) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.04"/>
                    <measurement group_id="O2" value="1.55" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Post-dose IRV (Inspiratory Reserve Volume) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Post-dose IRV (Inspiratory Reserve Volume) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.04"/>
                    <measurement group_id="O2" value="1.55" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Trough TLC (Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Trough TLC (Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.47" spread="0.09"/>
                    <measurement group_id="O2" value="7.39" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Trough TLC (Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Trough TLC (Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.52" spread="0.09"/>
                    <measurement group_id="O2" value="7.51" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Post-dose TLC (Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Post-dose TLC (Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.36" spread="0.09"/>
                    <measurement group_id="O2" value="7.36" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes</title>
        <description>Post-dose TLC (Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes</title>
          <description>Post-dose TLC (Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="0.09"/>
                    <measurement group_id="O2" value="7.47" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes (Percent)</title>
        <description>Trough RV/TLC (Residual Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes (Percent)</title>
          <description>Trough RV/TLC (Residual Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Percent of RV over TLC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.10" spread="0.54"/>
                    <measurement group_id="O2" value="57.18" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes (Percent)</title>
        <description>Trough RV/TLC (Residual Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes (Percent)</title>
          <description>Trough RV/TLC (Residual Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Percent of RV over TLC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.57" spread="0.56"/>
                    <measurement group_id="O2" value="57.47" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes (Percent)</title>
        <description>Post-dose RV/TLC (Residual Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes (Percent)</title>
          <description>Post-dose RV/TLC (Residual Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Percent of RV over TLC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.79" spread="0.54"/>
                    <measurement group_id="O2" value="55.02" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes (Percent)</title>
        <description>Post-dose RV/TLC (Residual Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes (Percent)</title>
          <description>Post-dose RV/TLC (Residual Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Percent of RV over TLC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.09" spread="0.57"/>
                    <measurement group_id="O2" value="55.07" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes (Percent)</title>
        <description>Trough TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes (Percent)</title>
          <description>Trough TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Percent of TGV over TLC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.87" spread="0.47"/>
                    <measurement group_id="O2" value="70.94" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes (Percent)</title>
        <description>Trough TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes (Percent)</title>
          <description>Trough TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Percent of TGV over TLC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.59" spread="0.47"/>
                    <measurement group_id="O2" value="70.99" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes (Percent)</title>
        <description>Post-dose TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes (Percent)</title>
          <description>Post-dose TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Percent of TGV over TLC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.65" spread="0.49"/>
                    <measurement group_id="O2" value="68.85" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Volumes (Percent)</title>
        <description>Post-dose TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Volumes (Percent)</title>
          <description>Post-dose TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)</description>
          <population>FAS using imputed values</population>
          <units>Percent of TGV over TLC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.43" spread="0.49"/>
                    <measurement group_id="O2" value="69.22" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slow Vital Capacity (SVC)</title>
        <description>Trough SVC (Slow Vital Capacity) after 8 weeks (measured by spirometry)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Slow Vital Capacity (SVC)</title>
          <description>Trough SVC (Slow Vital Capacity) after 8 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="0.05"/>
                    <measurement group_id="O2" value="3.12" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slow Vital Capacity (SVC)</title>
        <description>Trough SVC (Slow Vital Capacity) after 4 weeks (measured by spirometry)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Slow Vital Capacity (SVC)</title>
          <description>Trough SVC (Slow Vital Capacity) after 4 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="0.05"/>
                    <measurement group_id="O2" value="3.12" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slow Vital Capacity (SVC)</title>
        <description>Post-dose SVC (Slow Vital Capacity) after 8 weeks (measured by spirometry)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Slow Vital Capacity (SVC)</title>
          <description>Post-dose SVC (Slow Vital Capacity) after 8 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" spread="0.05"/>
                    <measurement group_id="O2" value="3.28" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slow Vital Capacity (SVC)</title>
        <description>Post-dose SVC (Slow Vital Capacity) after 4 weeks (measured by spirometry)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Slow Vital Capacity (SVC)</title>
          <description>Post-dose SVC (Slow Vital Capacity) after 4 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="0.05"/>
                    <measurement group_id="O2" value="3.27" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Trough FEV1 (Forced Expiratory Volume in 1 second) after 8 weeks (measured by spirometry)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Trough FEV1 (Forced Expiratory Volume in 1 second) after 8 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.03"/>
                    <measurement group_id="O2" value="1.44" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Trough FEV1 (Forced Expiratory Volume in 1 second) after 4 weeks (measured by spirometry)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Trough FEV1 (Forced Expiratory Volume in 1 second) after 4 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.03"/>
                    <measurement group_id="O2" value="1.45" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) after 8 weeks (measured by spirometry)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) after 8 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.03"/>
                    <measurement group_id="O2" value="1.55" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) after 4 weeks (measured by spirometry)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) after 4 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.03"/>
                    <measurement group_id="O2" value="1.55" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Trough percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 8 weeks (measured by spirometry)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Trough percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 8 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Percent of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.27" spread="0.78"/>
                    <measurement group_id="O2" value="49.12" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Trough percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 4 weeks (measured by spirometry)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Trough percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 4 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Percent of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.40" spread="0.79"/>
                    <measurement group_id="O2" value="49.26" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Post-dose percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 8 weeks (measured by spirometry)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Post-dose percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 8 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Percent of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.99" spread="0.82"/>
                    <measurement group_id="O2" value="52.59" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Post-dose percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 4 weeks (measured by spirometry)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Post-dose percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 4 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Percent of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.96" spread="0.82"/>
                    <measurement group_id="O2" value="52.64" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC)</title>
        <description>Trough FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC)</title>
          <description>Trough FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="0.05"/>
                    <measurement group_id="O2" value="2.94" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC)</title>
        <description>Trough FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC)</title>
          <description>Trough FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="0.05"/>
                    <measurement group_id="O2" value="2.93" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC)</title>
        <description>Post-dose FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC)</title>
          <description>Post-dose FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="0.05"/>
                    <measurement group_id="O2" value="3.11" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC)</title>
        <description>Post-dose FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC)</title>
          <description>Post-dose FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="0.05"/>
                    <measurement group_id="O2" value="3.11" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Over FVC (Percent)</title>
        <description>Trough FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Over FVC (Percent)</title>
          <description>Trough FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Percent of FEV1 over FVC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.16" spread="0.68"/>
                    <measurement group_id="O2" value="49.67" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Over FVC (Percent)</title>
        <description>Trough FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Over FVC (Percent)</title>
          <description>Trough FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Percent of FEV1 over FVC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.74" spread="0.82"/>
                    <measurement group_id="O2" value="50.62" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Over FVC (Percent)</title>
        <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Over FVC (Percent)</title>
          <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Percent of FEV1 over FVC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.77" spread="0.72"/>
                    <measurement group_id="O2" value="50.66" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Over FVC (Percent)</title>
        <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Over FVC (Percent)</title>
          <description>Post-dose FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)</description>
          <population>FAS using imputed values</population>
          <units>Percent of FEV1 over FVC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.90" spread="0.73"/>
                    <measurement group_id="O2" value="50.91" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Intensity During Exercise</title>
        <description>Isotime Borg dyspnea scale after 8 weeks, Unit on a Scale (min. 0, max 10), 0 = no dyspnea, 10 = worst imaginable dyspnea</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Intensity During Exercise</title>
          <description>Isotime Borg dyspnea scale after 8 weeks, Unit on a Scale (min. 0, max 10), 0 = no dyspnea, 10 = worst imaginable dyspnea</description>
          <population>FAS using imputed values</population>
          <units>Unit on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" spread="0.13"/>
                    <measurement group_id="O2" value="4.98" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Intensity During Exercise</title>
        <description>Isotime Borg dyspnea scale after 4 weeks, Unit on a Scale (min. 0, max. 10), 0 = no dyspnea, 10 = worst imaginable dyspnea</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Intensity During Exercise</title>
          <description>Isotime Borg dyspnea scale after 4 weeks, Unit on a Scale (min. 0, max. 10), 0 = no dyspnea, 10 = worst imaginable dyspnea</description>
          <population>FAS using imputed values</population>
          <units>Unit on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" spread="0.13"/>
                    <measurement group_id="O2" value="5.02" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Intensity During Exercise</title>
        <description>Isotime Borg leg discomfort scale after 8 weeks, Unit on a Scale (min. 0, max. 10), 0 = no leg dyscomfort, 10 = worst imaginable leg dyscomfort</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Intensity During Exercise</title>
          <description>Isotime Borg leg discomfort scale after 8 weeks, Unit on a Scale (min. 0, max. 10), 0 = no leg dyscomfort, 10 = worst imaginable leg dyscomfort</description>
          <population>FAS using imputed values</population>
          <units>Unit on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" spread="0.15"/>
                    <measurement group_id="O2" value="4.53" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Intensity During Exercise</title>
        <description>Isotime Borg leg discomfort scale after 4 weeks, Unit on a Scale (min. 0, max. 10), 0 = no leg dyscomfort, 10 = worst imaginable leg dyscomfort</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Intensity During Exercise</title>
          <description>Isotime Borg leg discomfort scale after 4 weeks, Unit on a Scale (min. 0, max. 10), 0 = no leg dyscomfort, 10 = worst imaginable leg dyscomfort</description>
          <population>FAS using imputed values</population>
          <units>Unit on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="0.15"/>
                    <measurement group_id="O2" value="4.63" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea and Leg Discomfort</title>
        <description>Peak Borg dyspnea scale after 8 weeks, Unit on a Scale (min. 0, max 10)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea and Leg Discomfort</title>
          <description>Peak Borg dyspnea scale after 8 weeks, Unit on a Scale (min. 0, max 10)</description>
          <population>FAS using imputed values</population>
          <units>Unit on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.52" spread="2.36"/>
                    <measurement group_id="O2" value="6.61" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea and Leg Discomfort</title>
        <description>Peak Borg leg discomfort scale after 8 weeks, Unit on a Scale (min. 0, max 10)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea and Leg Discomfort</title>
          <description>Peak Borg leg discomfort scale after 8 weeks, Unit on a Scale (min. 0, max 10)</description>
          <population>FAS using imputed values</population>
          <units>Unit on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.10" spread="3.03"/>
                    <measurement group_id="O2" value="5.86" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Locus of Symptom Limitation at Peak Exercise During Exercise</title>
        <description>Reason for stopping exercise at baseline (leg discomfort, breathing discomfort, both or none)</description>
        <time_frame>baseline</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Locus of Symptom Limitation at Peak Exercise During Exercise</title>
          <description>Reason for stopping exercise at baseline (leg discomfort, breathing discomfort, both or none)</description>
          <population>FAS using imputed values</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leg discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breathing discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both (leg and breathing discomfort)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Locus of Symptom Limitation at Peak Exercise During Exercise</title>
        <description>Reason for stopping exercise after 4 weeks (leg discomfort, breathing discomfort, both or none)</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Locus of Symptom Limitation at Peak Exercise During Exercise</title>
          <description>Reason for stopping exercise after 4 weeks (leg discomfort, breathing discomfort, both or none)</description>
          <population>FAS using imputed values</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leg discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breathing discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both (leg and breathing discomfort)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Locus of Symptom Limitation at Peak Exercise During Exercise</title>
        <description>Reason for stopping exercise after 8 weeks (leg discomfort, breathing discomfort, both or none)</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS using imputed values</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium + Salmeterol</title>
            <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1 or 2</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone + Salmeterol</title>
            <description>Flu+Sal 500+50mcg b.i.d. in Period 1 or 2</description>
          </group>
        </group_list>
        <measure>
          <title>Locus of Symptom Limitation at Peak Exercise During Exercise</title>
          <description>Reason for stopping exercise after 8 weeks (leg discomfort, breathing discomfort, both or none)</description>
          <population>FAS using imputed values</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leg discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breathing discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both (leg and breathing discomfort)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From drug administration until end of second treatment period plus 30 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tiotropium + Salmeterol (Period 1)</title>
          <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 1</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium + Salmeterol (Period 2)</title>
          <description>Tio 18mcg o.d. + Sal 50mcg b.i.d. in Period 2</description>
        </group>
        <group group_id="E3">
          <title>Fluticasone + Salmeterol (Period 1)</title>
          <description>Flu+Sal 500+50mcg b.i.d. in Period 1</description>
        </group>
        <group group_id="E4">
          <title>Fluticasone + Salmeterol (Period 2)</title>
          <description>Flu+Sal 500+50mcg b.i.d. in Period 2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Musculeskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

